[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:folate-receptor-alpha":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Folate Receptor Alpha",9,8,[8,16,23,29,36,42,48,55,61],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03832361","Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:17:38.215063Z","2026-05-05T02:43:29.680225Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07213804","A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer",[20],"Phase 3","2026-08-26T02:17:27.435233Z","2026-07-05T05:32:16.660912Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05887609","An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib",[12],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:29.336719Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05920798","Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[33],"Phase 1\u002FPhase 2","2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.054306Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06890338","A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",[12],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.627515Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05579366","Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01\u002F PRO1184-001)",[33],"2026-08-26T02:17:02.694423Z","2026-07-05T05:32:16.807199Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT06431594","A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)",[52],"Phase 1","2026-08-26T02:15:38.131683Z","2026-07-05T05:32:16.753991Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07039526","Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.",[12],"2026-08-26T02:17:33.807405Z","2026-05-05T02:43:26.932827Z",{"nct_id":62,"title":63,"phases":64,"status":65,"updated_at":66,"content_modified":67},"NCT05445778","Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:31:16.569358Z","2026-05-05T02:43:29.220044Z"]